You are viewing: Canada AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The Canada AI in Oncology Market was valued at $62.4 Million in 2024 and projected to reach to $257.3 Million by 2029, representing a compound annual growth rate of 26.6%. Canada's AI in Oncology market is poised for accelerated expansion through 2029, driven by increasing cancer incidence, healthcare provider demand for diagnostic efficiency, and substantial investments in health technology infrastructure.

Canada AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Canada AI in Oncology Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 26.6%, reflecting Canada's strong adoption of artificial intelligence technologies in cancer diagnosis, treatment planning, and patient management.
  • Canada's healthcare infrastructure, combined with significant investment in digital health innovation, positions the country as a key player in the North American AI oncology landscape. The expansion of Canada's AI in Oncology market is driven by increasing prevalence of cancer cases, growing demand for precision medicine, and substantial government and private sector funding for healthcare technology.
  • Canadian healthcare providers and research institutions are increasingly integrating AI-powered diagnostic tools and predictive analytics into oncology workflows.
  • Between 2024 and 2029, Canada is expected to see accelerated adoption of machine learning algorithms for tumor detection, treatment optimization, and clinical decision support systems. Canada's regulatory environment and emphasis on evidence-based healthcare create favorable conditions for AI oncology solutions.
  • The market's growth trajectory reflects both the clinical demand for advanced diagnostic capabilities and Canada's commitment to leveraging cutting-edge technology to improve cancer outcomes across the nation..

Key Market Statistics

  • CAGR (2024-2029) 26.6% CAGR
  • Market Size, 2024 ~USD 62.4 Million
  • Forecast, 2029 ~USD 257.3 Million
  • Country Canada

Canada AI in Oncology Market Overview

Market Valuation Growth :

Canada's AI in Oncology market is valued at $62.4 million in 2024, with projections reaching $257.3 million by 2029, demonstrating a robust 26.6% CAGR driven by increasing healthcare digitalization and cancer prevalence.

Advanced Healthcare Infrastructure :

Canada's publicly funded healthcare system and strong research institutions are accelerating AI adoption in oncology, with major medical centers investing in machine learning solutions for diagnostic imaging and treatment optimization.

Government Support & Funding :

Canadian federal and provincial initiatives, including innovation grants and digital health programs, are fostering AI development in cancer care, positioning Canada as a leader in healthcare AI innovation within North America.

Clinical Integration Momentum :

Canadian hospitals and cancer centers are rapidly integrating AI tools for pathology analysis, radiomics, and personalized treatment planning, with regulatory frameworks from Health Canada supporting faster adoption of validated AI solutions.

Canada AI in Oncology Market Dynamics

  • The country's universal healthcare system creates unique opportunities for large-scale AI implementation across provincial networks, while academic partnerships with institutions like University of Toronto and BC Cancer Agency strengthen innovation pipelines. Key growth catalysts include regulatory clarity from Health Canada, rising adoption of precision medicine approaches, and integration of AI into existing electronic health record systems.
  • With a 26.6% CAGR significantly outpacing global averages in certain segments, Canada represents a high-potential market for AI oncology vendors seeking North American expansion and healthcare systems seeking to improve patient outcomes while managing costs..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • Canada's AI in Oncology market is valued at $62.4 million in 2024 and is forecast to reach $257.3 million by 2029, representing a 26.6% CAGR.
      • Canada's strong healthcare infrastructure and digital health investment are accelerating adoption of AI-powered diagnostic and treatment planning tools.
      • Machine learning algorithms for tumor detection and clinical decision support are becoming increasingly integrated into Canadian oncology practices.
      • Canada's regulatory framework and emphasis on precision medicine create a favorable environment for sustained AI oncology market expansion through 2029.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      Canada AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      CANADA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030

      Segment202220232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTIONS4.15.46.78.410.613.416.921.427.226.2
      GOVERNMENT & REGULATORY AGENCIES1.41.82.22.73.44.25.26.68.224.5
      HEALTHCARE PAYERS11.31.62.12.63.24.15.16.525.7
      HEALTHCARE PROVIDERS18.32430.238.248.461.578.4100.2128.427.3
      MEDICAL DEVICE/ EQUIPMENT COMPANIES3.44.45.46.78.410.513.116.420.725
      OTHER END USERS0.70.91.11.31.622.433.622.5
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES9.21215.1192430.438.649.162.726.8
      TOTAL38.249.862.478.599125.1158.7201.8257.326.6

      Target Audience

      • Healthcare Technology Vendors : AI and software companies seeking to enter or expand in the Canadian oncology market need detailed market sizing, competitive analysis, and regulatory pathways to optimize product-market fit and go-to-market strategies.
      • Hospital & Cancer Center Administrators : Canadian healthcare leaders require market intelligence on AI solution capabilities, implementation costs, clinical outcomes, and vendor comparisons to make informed procurement decisions and justify technology investments.
      • Investment & Private Equity Firms : Investors evaluating opportunities in Canadian healthcare technology need comprehensive market data, growth projections, and competitive dynamics to assess portfolio companies and identify high-potential acquisition or funding targets.
      • Medical Device & Pharma Companies : Established healthcare organizations expanding into AI-driven oncology solutions require Canadian market insights, reimbursement landscapes, and clinical adoption trends to develop localized strategies and partnerships.
      • Government & Policy Makers : Federal and provincial health authorities need evidence-based market analysis to inform digital health policy, funding allocation, and regulatory frameworks supporting AI adoption in Canadian cancer care systems.

      Reasons to Buy this Report

      • Market-Specific Sizing & Forecasts : Access precise valuation data for Canada's AI in Oncology segment with detailed 2024-2029 projections, enabling accurate budget allocation and revenue forecasting for market entry or expansion strategies.
      • Competitive Landscape Intelligence : Identify key players, partnerships, and competitive positioning within Canada's oncology AI ecosystem, including insights into provincial healthcare procurement preferences and regulatory requirements.
      • Growth Driver Analysis : Understand Canada-specific factors accelerating adoption, including healthcare policy changes, funding mechanisms, clinical integration pathways, and barriers to entry unique to the Canadian market.
      • Investment & Partnership Opportunities : Discover strategic investment targets, acquisition candidates, and partnership opportunities with Canadian healthcare institutions, research centers, and technology vendors in the oncology AI space.
      • Regulatory & Reimbursement Insights : Navigate Health Canada's regulatory framework, provincial reimbursement models, and healthcare system requirements essential for successful product commercialization and market penetration in Canada.

      Frequently asked questions

      What is the current size of Canada's AI in Oncology market?

      Canada's AI in Oncology market was valued at $62.4 million USD in 2024 and is projected to grow to $257.3 million USD by 2029.

      What is the expected growth rate for Canada's AI in Oncology market?

      Canada's AI in Oncology market is expected to grow at a compound annual growth rate (CAGR) of 26.6% from 2024 to 2029.

      What are the primary drivers of growth in Canada's AI in Oncology market?

      Key growth drivers in Canada include rising cancer prevalence, increased demand for precision medicine, substantial healthcare technology funding, and integration of AI diagnostic tools into clinical workflows.

      How is Canada positioned within the North American AI Oncology market?

      Canada is a significant player in North America's AI Oncology market, leveraging its advanced healthcare infrastructure, regulatory framework, and investment in digital health innovation to drive adoption of AI-powered oncology solutions.

      What types of AI applications are being adopted in Canada's oncology sector?

      Canadian oncology providers are adopting machine learning algorithms for tumor detection, treatment planning optimization, predictive analytics, and clinical decision support systems to improve cancer diagnosis and patient outcomes.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status